1 / 28

Anticoagulation in Strokes

Anticoagulation in Strokes. Guidelines for the Early Management of Adults With Ischemic Stroke A Case Study References: Stroke 2007;38:1655 2007 American Heart Association, Inc. 1100: You are admitting a 68 yr old female to Observation from the ER with diagnosis of

meadow
Download Presentation

Anticoagulation in Strokes

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Anticoagulation in Strokes Guidelines for the Early Management of Adults With Ischemic Stroke A Case Study References: Stroke 2007;38:1655 2007 American Heart Association, Inc.

  2. 1100: You are admitting a 68 yr old female to Observation from the ER with diagnosis of TIA. She has a history of hypertension, controlled with Atenolol. Other meds: ASA 81mg daily and Multivitamins. ER course: Admitted to ER per EMS @ 0800 with complaints of facial numbness and left side weakness. Symptoms resolved 30 min. after arrival. CT was negative for hemorrhagic stroke. Initial NIH Stroke Scale assessment was 2. Her ER admission BP was 190/110 which Decreased to 160/94 without treatment.

  3. What additional information do you need? Red flags? What do you suspect? Interventions?

  4. National Institute of Health Stroke Scale

  5. 1100 Initial admission assessment: Abbreviated NIH Stroke scale remains unchanged at 0.

  6. What additional information do you need? Red flags? What do you suspect? Interventions?

  7. VS: BP-168/90 HR-72 R -16 • T- 98.1 SaO2 96% on RA

  8. 1300: You answer the call light. Family at bedside tell you she “can’t talk or move her arm.NIH Assessment:

  9. What additional information do you need? Red flags? What do you suspect? Interventions? • VS: BP-210/120 HR-88 R-20 T-98.5 • SaO2 – 94% You report to the doctor and a stat head CT is ordered. Why? What do you anticipate?

  10. t-PA STROKE EXCLUSION CRITERIAGUIDELINES ONLY, ADDITIONAL CONSIDERATIONS MAY APPLY TO INDIVIDUAL PATIENTS Absolute Contraindications:  Acute focal neurologic deficit not on the basis of focal ischemia.  Not medically evaluated & treatment begun within 3hrs. of onset of symptoms.  <18 years, > 77 (relative contraindication)  Female of child bearing potential without neg. pregnancy test.  Patient or representative unable to understand & give informed consent.  Sensory loss, ataxia, or dysarthria alone.  Sustained uncontrolled BP >180/105, need for IV tx to  BP One or more seizures at onset.  Hemorrhagic stroke, mass effect, or edema on baseline CT  Suspicion of subarachnoid hemorrhage  Intracranial neoplasm, AV malformation or aneurysm. • Known bleeding diathesis, illness with high risk of bleeding. • Severe complicated medical illness such as metastatic cancer or AIDS that would complicate treatment.

  11. Preexisting neurologic, psychiatric or other illness that would complicate treatment.Major surgery within the last 14 days GI or GU hemorrhage within the last 21 days Previous cerebral infarction within the last 3 months Arterial puncture at non-compressible site within the last 7 days Taking Coumadin or Heparin within previous 48 hours or receives low molecular weight heparinoids. Platelet count below 100,000 Blood Glucose <50 - >400 Significant head trauma within the last 3 months History of intracranial hemorrhage. Rapidly improving neurologic deficit. PT >15 seconds

  12. Relative Contraindications:Severe neurological deficits at discretion of neurologist.Age >77 yearsSerious trauma in the last 14 days.Acute myocardial infarction.Pericarditis or subacute bacterial endocarditisSignificant liver or kidney dysfunctionDiabetic hemorrhagic retinopathyOccluded arterial/venous cannula at seriously infected site.

  13. THROMBOLYTIC THERAPY PATIENT SELECTION CHECKLIST/HISTORY HAVE YOU HAD ANY OF THE FOLLOWING: Recent surgery (within 4 - 6 weeks) Recent dental procedure (within 2-3 days) Falls or severe trauma (chest, head, back, abdomen) in the past monthBruises, abrasion, cutsStrep infection (in last 3 months) History of allergic reaction to streptokinase DO YOU HAVE A HISTORY OF Hypertension - diastolic >110 and/or systolic >180 Blood clotting problems/bleeding disorders Carcinoma/cancer Ulcers Recent bloody/tarry stools or vomited blood in past 2 weeks Active tuberculosis Stroke, aneurysm, intracranial neoplasm, AV malformation Back or head surgery (in last 2 months) Heart valve infection/left heart thrombus (in last 2 months) Severe skin or mucous membrane disease CPR Diabetic retinopatthy, hemorrhagic ophthalamic condition Advanced liver or kidney disease Recent drug or alcohol ingestion Diabetes (if yes, how long) IDDM or NIDDM PREGNANT OR GIVEN BIRTH WITHIN THE LAST 10 DAYSHave you taken in the last 48hrs.

  14. The Head CT is negative for hemorrhagic stroke. He asks you to page the neurologist on call. • What do you anticipate?

  15. Guidelines for Early Management of Adults with Ischemic Stroke: • D. Conclusions and RecommendationsIntravenous administration of rtPA is the only FDA-approved medical therapy for treatment of patients with acute ischemic stroke.3 Its use is associated with improved outcomes for a broad spectrum of patients who can be treated within 3 hours of stroke onset. Earlier treatment (ie, within 90 minutes) may be more likely to result in a favorable outcome. Later treatment, at 90 to 180 minutes, also is beneficial. Patients with major strokes (NIHSS score >22) have a very poor prognosis, but some positive treatment effect with rtPA has been documented.329 Because the risk of hemorrhage is considerable among patients with severe deficits, the decision to treat with rtPA should be made with caution. Treatment with rtPA is associated with symptomatic intracranial hemorrhage, which may be fatal. In the original NINDS trials, the risk of symptomatic bleeding was 6%.100 Recent community-based studies and registries report lower rates of hemorrhage.269,330–333 Recommendations for the management of intracranial hemorrhage after treatment with rtPA are provided in the AHA Stroke Council’s updated guideline statement on management of intracerebral hemorrhage, which is being issued contemporaneously with this statement. The best methods for preventing bleeding complications are careful selection of patients and scrupulous ancillary care, especially close observation, and monitoring of the patient with early treatment of arterial hypertension. Factors that affect decisions about administration of rtPA are outlined in Table 11, and the treatment regimen for administration of rtPA is included in Table 12. Case series have suggested that thrombolysis may be used in patients with seizures at the time of presentation when evidence suggests that residual deficits are due to ischemia rather than the postictal state.334,335 The use of anticoagulants and antiplatelet agents should be delayed for 24 hours after treatment.

  16. Intra-arterial Thrombolysis • Class I Recommendations • Intra-arterial thrombolysis is an option for treatment of selected patients who have major stroke of <6 hours’ duration due to occlusions of the MCA and who are not otherwise candidates for intravenous rtPA (Class I, Level of Evidence B). This recommendation has not changed since previous guidelines. • Treatment requires the patient to be at an experienced stroke center with immediate access to cerebral angiography and qualified interventionalists. Facilities are encouraged to define criteria to credential individuals who can perform intra-arterial thrombolysis (Class I, Level of Evidence C). This recommendation has been added since previous guidelines. • Class II Recommendation • Intra-arterial thrombolysis is reasonable in patients who have contraindications to use of intravenous thrombolysis, such as recent surgery (Class IIa, Level of Evidence C). This recommendation was not included in the previous guideline. • Class III Recommendation • The availability of intra-arterial thrombolysis should generally not preclude the intravenous administration of rtPA in otherwise eligible patients (Class III, Level of Evidence C). This recommendation has not changed from previous guidelines.

  17. What have we forgotten? • If systolic > 180 and/or diastolic > 105, notify MD. May consider: • Labetalol (Normodyne) 10mg IV over 1-2 min. May repeat and/or double q 10 min. up to total of 150mg. • Following first dose of Labetalol, infuse 2-8mg/min.

  18. You have an order to begin TpA per protocol. Your patient weighs 80kg.

  19. Page to St. Als ER MD on call, will facilitate communication with Neurologist on call. • Life Flight on Standby • TpA IV 0.9mg/kg total (max dose 90mg) 10% bolus over 1 min, infuse remainder over 60 min. • If intracranial hemorrhage is suspected (acute neurological deterioration, new headache, sudden/acute hypertension, nausea/vomiting) notify MD & anticipate orders to: • Discontinue TpA infusion • STAT CT • Stat PT,PTT, platelet count • Type & cross • Notify receiving Neurologist

  20. 1400: • TpA bolus & Infusion started. • Life Flight ETA 30 min. • BP controlled with Labetalol infusion @ 2mg/min. 1420: Change in neuro status:

  21. NIH Assessment:

  22. Red flags? What do you suspect? Interventions? • The physician orders a stat CT but does not stop the infusion • CT results are negative for hemmhoragic stroke. • 1440: Life Flight arrives

  23. NIH Assessment at time of transfer:

  24. Questions?Discussion?NIH Stoke Scale Practice

More Related